PHARMAC is pleased that the Government has announced an uplift in PHARMAC’s funding.
The Combined Pharmaceutical Budget (CPB) will be increased to a record level of $985 million in 2018/19 - an increase of
just under $114.2 million on the 2017/18 CPB level.
From 1 July 2018, PHARMAC will manage all public expenditure on medicines - whether used in the community or in
hospital, and this means that all remaining DHB’s expenditure will be part of the CPB.
Due to the power of the PHARMAC model, this is likely to provide future savings of around $200 million over four years
for Vote Health – achievable by applying the PHARMAC model to the full portfolio of medicines.
PHARMAC will continue to invest in new medicines and technology that best meet the health needs of New Zealanders.
PHARMAC has proven its ability to return savings for the health sector, while at the same time funding new treatments,
as well as managing the growth in usage of existing funded treatments.
Read more about how the PHARMAC model works, on the PHARMAC website